New Meningitis Vaccine Nearly Eliminated Disease In Chad, Study Says

“Use of a new vaccine in Chad has all but eliminated meningitis, according to a study that boosts the prospects for defeating one of the most feared infections across central Africa,” the Financial Times reports. “Just 57 cases of meningitis were identified last year in regions of Chad where MenAfriVac had been administered, compared with more than 3,800 cases in people in other parts of the country who were not vaccinated,” the newspaper writes, adding, “The figures, reported in the Lancet medical journal by academics led by the Centre de Support de Santé International in Chad and the London School of Hygiene and Tropical Medicine, lend support to efforts to introduce mass vaccination with the product across … Africa’s ‘meningitis belt'” (Jack, 9/12). “Deadly epidemics of meningitis A are frequent in Africa’s so-called ‘meningitis belt,’ a band of … sub-Saharan countries which extends from Senegal to Ethiopia,” according to the Information Daily, which notes, “It is estimated that around 450 million people are at risk” (9/12). “Infants, children and young adults are most at risk of meningitis, an inflammation of the membrane around the brain and spinal cord that can cause death or disability, including deafness, paralysis and limb infection leading to amputation,” a London School of Hygiene and Tropical Medicine press release states (9/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.